Trump nominates policy aide Dr. Heidi Overton as next FDA commissioner

President Donald Trump announced on Wednesday that he is nominating Dr. Heidi Overton, a physician and White House deputy assistant for domestic policy, as the next head of the Food and Drug Administration (FDA). Overton, who graduated from the University of New Mexico with a medical doctorate, has worked closely with Health and Human Services Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, the director of the Centers for Medicare and Medicaid Services.

Trump praised her for her contributions to the "MOST TRANSFORMATIVE Health Agenda in History" and emphasized her ability to tackle difficult issues and deliver solutions that benefit the nation.

Overton's nomination comes amid efforts to ensure the U.S. remains a world leader in scientific discovery and cures. She will collaborate with Secretary Kennedy and Dr. Oz to accelerate the delivery of faster cures, boost American innovation, reform clinical trials, lower drug prices, and achieve further successes. Overton was present during the signing of an executive order by Trump that recommends limits and changes to childhood vaccines earlier this month.

Despite her impressive credentials, including a residency in general surgery at Johns Hopkins University School of Medicine and her role as a White House fellow during Trump's first term, Overton faces Senate confirmation. Some Republicans, notably outgoing Sen. Bill Cassidy of Louisiana, have expressed concerns about her nomination.

Cassidy, a doctor himself, worries that her lack of managerial experience may not adequately prepare her to lead the FDA, which is currently dealing with staffing and morale issues. Cassidy also criticized Overton's involvement in the recent vaccine executive order, expressing doubts about her commitment to promoting sound science and protecting children's health.

The FDA is currently led by acting commissioner Kyle Diamantas, following the resignation of Dr. Marty Makary in May due to internal disputes over flavored e-cigarettes. Overton's nomination is expected to face scrutiny as critics question her suitability for the role and her stance on various health policies.